Gland Pharma Share Price Jumps Over 11% Post Q2 FY25 Results

Gland Pharma’s share rose over 12% on Tuesday, November 5, 2024. However, the stock has dropped 24% over the last three months and has remained mostly flat over the past year. In contrast, the Nifty Pharma index has gained 50% during the same period. 

Financial Results 

On November 4, 2024, Gland Pharma announced its Q2 FY25 financial results. The company reported a 2.36% increase in revenue compared to last year’s period, but profits fell significantly by 15.74%. Revenue showed a slight growth of 0.29% compared to the previous quarter, while profit increased by 13.75%.

Expense Management

Gland Pharma’s selling, general, and administrative expenses decreased by 6.68% from the previous quarter but rose by 3.29% year over year. This variation illustrates the difficulties the company faces in controlling costs amid shifting market conditions.

Operating Income Insights

Operating income rose by 17.86% from the last quarter but decreased by 16.29% compared to the same quarter last year. This indicates that Gland Pharma is improving its operational efficiency in the short term but is struggling to maintain profitability over the long run.

Earnings Per Share

Earnings per share (EPS) for Q2 were ₹9.93, reflecting a 15.7% decline year over year. This drop in EPS mirrors the company’s overall reduction in profitability.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.